Inhibition of osteosarcoma cell progression by MacroH2A via the downregulation of cyclin D and cyclin‑dependent kinase genes

Yang,Pu; Yin,Ke; Zhong,Da; Liao,Qiande; Li,Kanghua

doi:10.3892/mmr.2014.2903

Inhibition of osteosarcoma cell progression by MacroH2A via the downregulation of cyclin D and cyclin‑dependent kinase genes

Authors:
- Pu Yang
- Ke Yin
- Da Zhong
- Qiande Liao
- Kanghua Li
View Affiliations

Affiliations: Department of Orthopedic Surgery, The Xiangya Hospital of Central South University, Changsha, Hunan 410008, P.R. China
Published online on: November 7, 2014 https://doi.org/10.3892/mmr.2014.2903
Pages: 1905-1910

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MacroH2A is a histone modification factor the activity of which has been acutely studied in cancer progression, and a number of studies have shown that the progression of certain types of cancer is under regulation by MacroH2A. However, information regarding the underlying molecular mechanisms of MacroH2A inhibition on the cell cycle remains elusive, and elucidating this process may aid in the production of novel treatment strategies. The aim of the current study was to investigate the inhibitory effects of MacroH2A on osteosarcoma cell progression, and the possible molecular mechanisms of this process. MacroH2A overexpression and interference vectors were designed and transfected into U2‑OS osteosarcoma cells. The cells underwent reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), western blot analysis and immunofluorescence assays. The apoptosis rate and cell cycle stage were assayed using flow cytometry. The results revealed that the overexpression of MacroH2A inhibited the progression of U2‑OS osteosarcoma cells, and the cells were arrested at the G2/M stage of the cell cycle. The molecular mechanism by which MacroH2A suppresses the cell progression involves the inhibition of the expression of cyclin D and cyclin‑dependent kinase (CDK) genes, including cyclin D1, cyclin D2, CDK4, CDK6 and CDK8. Taken together, the present results revealed that MacroH2A is an important modifier of chromatin that downregulates the progression of osteosarcoma cells and triggers disturbance of the cell cycle via the downregulation of cyclin D and CDK genes.

View Figures

View References

1	Portela A and Esteller M: Epigenetic modifications and human disease. Nat Biotechnol. 28:1057–1068. 2010. View Article : Google Scholar : PubMed/NCBI
2	Baylin SB and Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
3	Kulaeva OI, Gaykalova DA and Studitsky VM: Transcription through chromatin by RNA polymerase II: histone displacement and exchange. Mutat Res. 618:116–129. 2007. View Article : Google Scholar : PubMed/NCBI
4	Neely KE and Workman JL: The complexity of chromatin remodeling and its links to cancer. Biochim Biophys Acta. 1603:19–29. 2002.PubMed/NCBI
5	Hake S, Xiao A and Allis C: Linking the epigenetic ‘language’ of covalent histone modifications to cancer. Br J Cancer. 90:761–769. 2004. View Article : Google Scholar : PubMed/NCBI
6	Strahl BD and Allis CD: The language of covalent histone modifications. Nature. 403:41–45. 2000. View Article : Google Scholar : PubMed/NCBI
7	Peterson CL and Laniel MA: Histones and histone modifications. Curr Biol. 14:R546–R551. 2004. View Article : Google Scholar : PubMed/NCBI
8	Redon C, Pilch D, Rogakou E, et al: Histone H2a variants H2AX and H2AZ. Curr Opin Genet Dev. 12:162–169. 2002. View Article : Google Scholar : PubMed/NCBI
9	Pehrson JR and Fried VA: MacroH2A, a core histone containing a large nonhistone region. Science. 257:1398–1400. 1992. View Article : Google Scholar : PubMed/NCBI
10	Kustatscher G, Hothorn M, Pugieux C, Scheffzek K and Ladurner AG: Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol. 12:624–625. 2005. View Article : Google Scholar : PubMed/NCBI
11	Brooks WH: X chromosome inactivation and autoimmunity. Clin Rev Allergy Immunol. 39:20–29. 2010. View Article : Google Scholar
12	Chadwick BP and Willard HF: Histone H2A variants and the inactive X chromosome: identification of a second macroH2A variant. Hum Mol Genet. 10:1101–1113. 2001. View Article : Google Scholar : PubMed/NCBI
13	Kapoor A, Goldberg MS, Cumberland LK, et al: The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature. 468:1105–1109. 2010. View Article : Google Scholar : PubMed/NCBI
14	Rickert P, Seghezzi W, Shanahan F, Cho H and Lees E: Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene. 12:2631–2640. 1996.PubMed/NCBI
15	Donner AJ, Szostek S, Hoover JM and Espinosa JM: CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell. 27:121–133. 2007. View Article : Google Scholar : PubMed/NCBI
16	Sánchez I and Dynlacht BD: New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol. 16:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
17	Satyanarayana A and Kaldis P: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
18	Fisher RP: CDKs and cyclins in transition(s). Curr Opin Genet Dev. 7:32–38. 1997. View Article : Google Scholar : PubMed/NCBI
19	Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
20	Andreassi MG: DNA damage, vascular senescence and atherosclerosis. J Mol Med. 86:1033–1043. 2008. View Article : Google Scholar : PubMed/NCBI
21	Morgan DO: Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
22	Tyson JJ, Csikasz-Nagy A and Novak B: The dynamics of cell cycle regulation. Bioessays. 24:1095–1109. 2002. View Article : Google Scholar : PubMed/NCBI
23	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
24	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
25	Sporn JC, Kustatscher G, Hothorn T, et al: Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene. 28:3423–3428. 2009. View Article : Google Scholar : PubMed/NCBI
26	Novikov L, Park JW, Chen H, et al: QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol Cell Biol. 31:4244–4255. 2011. View Article : Google Scholar : PubMed/NCBI
27	Haugstetter A, Loddenkemper C, Lenze D, et al: Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer. 103:505–509. 2010. View Article : Google Scholar : PubMed/NCBI
28	Buschbeck M and Di Croce L: Approaching the molecular and physiological function of macroH2A variants. Epigenetics. 5:118–123. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zhang R and Adams PD: Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle. 6:784–789. 2007. View Article : Google Scholar : PubMed/NCBI
30	Collado M, Gil J, Efeyan A, et al: Tumour biology: senescence in premalignant tumours. Nature. 436:642. 2005. View Article : Google Scholar : PubMed/NCBI
31	Dardenne E, Pierredon S, Driouch K, et al: Splicing switch of an epigenetic regulator by RNA helicases promotes tumor-cell invasiveness. Nat Struct Mol Biol. 19:1139–1146. 2012. View Article : Google Scholar : PubMed/NCBI
32	Shtutman M, Zhurinsky J, Simcha I, et al: The Cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 96:5522–5527. 1999. View Article : Google Scholar : PubMed/NCBI
33	Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
34	Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
35	Gray N, Détivaud L, Doerig C and Meijer L: ATP-site directed inhibitors of Cyclin-dependent kinases. Curr Med Chem. 6:859–876. 1999.PubMed/NCBI
36	Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI